Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.
about
Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosisOral anti-pseudomonal antibiotics for cystic fibrosisMacrolide antibiotics for cystic fibrosisMacrolide antibiotics for cystic fibrosisCombination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosisOral anti-pseudomonal antibiotics for cystic fibrosisMacrolide antibiotics for cystic fibrosisMacrolide antibiotics for cystic fibrosisMeasuring and reporting quality of life outcomes in clinical trials in cystic fibrosis: a critical reviewOral anti-pseudomonal antibiotics for cystic fibrosisNew and emerging targeted therapies for cystic fibrosisComputed tomography dose optimisation in cystic fibrosis: A reviewThe Evolution of Cystic Fibrosis CareCystic fibrosis chronic rhinosinusitis: a comprehensive reviewChronic rhinosinusitis and nasal polyposis in cystic fibrosis: update on diagnosis and treatmentEfficacy of β-Lactam-plus-Macrolide Combination Therapy in a Mouse Model of Lethal Pneumococcal PneumoniaImpact of Azithromycin on the Quorum Sensing-Controlled Proteome of Pseudomonas aeruginosaPA3297 Counteracts Antimicrobial Effects of Azithromycin in Pseudomonas aeruginosa.Use of FEV1 in cystic fibrosis epidemiologic studies and clinical trials: A statistical perspective for the clinical researcher.Background and EpidemiologyBiofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics.Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.From in vitro to in vivo Models of Bacterial Biofilm-Related Infections.Exacerbations in cystic fibrosis: 2 . prevention.A pilot trial on safety and efficacy of erythrocyte-mediated steroid treatment in CF patientsAssociation of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis.Impact of macrolide therapy in patients hospitalized with Pseudomonas aeruginosa community-acquired pneumonia.Prognostic factors in hospitalized community-acquired pneumonia: a retrospective study of a prospective observational cohortAzithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosisThe effects of inhaled aztreonam on the cystic fibrosis lung microbiome.Cystic fibrosis: exploiting its genetic basis in the hunt for new therapiesPopulation pharmacokinetics of azithromycin in whole blood, peripheral blood mononuclear cells, and polymorphonuclear cells in healthy adults.Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapyOral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis.Effects of six-week clarithromycin therapy in corticosteroid-dependent asthma: A randomized, double-blind, placebo-controlled pilot study.Quenching the quorum sensing system: potential antibacterial drug targets.Pseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatmentDesign and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint.Azithromycin decreases NALP3 mRNA stability in monocytes to limit inflammasome-dependent inflammation.Molecular basis of azithromycin-resistant Pseudomonas aeruginosa biofilms
P2860
Q24188024-16295C8D-ECAD-4BF2-962F-7F26EB8DA347Q24202879-7FEB4C8F-8BA0-4F69-B3C1-5A76FA3715A4Q24202885-21DCC7FA-0DE4-4335-8920-346EAE0A5FAAQ24234430-4C052DE1-E650-4A2D-8736-0651108E5614Q24242073-A7C8B88F-D5DB-4754-AB30-647791175762Q24243916-0FA02BA0-C773-4DFA-8CC7-DCE12780D749Q24247243-83D96577-F5EB-47DA-95B4-A726E050A660Q24250150-E34C2434-1D91-40FC-848B-B670AF54E2CEQ24795582-36F91A16-D9AD-4ACB-9DE7-C716D0C0D011Q26471106-9664FF2D-5ADD-46DE-B7D6-50181924236BQ26749278-60DF05FB-9137-4065-B84D-24B28D763E3FQ26751283-D047908D-B99E-423A-BA2B-E77991E8BC31Q26999299-6F9489BC-144A-400F-89D2-A66DF4C39DADQ27003313-0E67F7B8-CB5D-42C3-A654-FDADDB52A74CQ28080762-154359EA-0C3D-4D83-9688-F827B4E41EF8Q28390204-E7924118-D33B-4B40-856E-E2EBBDB51712Q28552822-26FA7294-1608-435B-84B3-EE8AC509B9ECQ29346778-2DDA7D2E-6804-4C6B-B428-F597F30BCDACQ30238814-7A67525E-18D6-4E85-BE28-01A978112D85Q30248742-290A91E5-C0AC-4DF1-B401-6F6911CB4F93Q30403958-E51A0A84-04C3-4BAA-B4D1-55A0DAFCDBEDQ30413773-9F5E463A-A8BB-4FC3-8E8F-F254C9AC4BD1Q30424697-7F35FA55-71EC-46A4-8DCF-88152303067DQ30480308-20595F8C-FD98-42C5-BDBC-A45D235E08D9Q30816650-BD4BEFF6-59E2-490A-AD69-D0AA42CBBB83Q33483203-8ADF9728-7060-40D8-BE25-FA669BA9742AQ33572569-FFE16076-A9CD-4EB8-86A0-1208D3D108D3Q33630499-45E5CDE1-373A-4808-9BED-865B0627F945Q33640512-AF88C9EC-5004-46EF-AB5C-82F30BF17CC7Q33644835-36A0CEB0-4413-43A6-A7B7-837A7ECB7415Q33664918-DE027D14-0862-44F0-AFC0-AD088F7CABC6Q33689718-0D4E78F0-3A2F-44EC-BE9E-6223597E43B0Q33697276-A851D80C-516C-4D2C-B45D-634AABC1C799Q33725822-11C26097-5D24-4325-9589-489899898418Q33738775-DBBED00C-7246-4DF8-BDDF-CD5671830184Q33805168-9490A230-92D3-4077-A0FE-E1111FDAE03AQ33824149-D5646A40-D33E-4367-A167-DE6BA4C01014Q33836302-020B2459-E69B-49AB-8C37-0FFF04041478Q33850879-45C5E792-F97E-4DC3-924D-5C7624D80AABQ33935451-28849781-D041-4720-83E3-55C65DE83AA5
P2860
Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Azithromycin in patients with ...... a randomized controlled trial.
@en
Azithromycin in patients with ...... a randomized controlled trial.
@nl
type
label
Azithromycin in patients with ...... a randomized controlled trial.
@en
Azithromycin in patients with ...... a randomized controlled trial.
@nl
prefLabel
Azithromycin in patients with ...... a randomized controlled trial.
@en
Azithromycin in patients with ...... a randomized controlled trial.
@nl
P2093
P921
P356
P1476
Azithromycin in patients with ...... a randomized controlled trial.
@en
P2093
Alexandra L Quittner
Ann Yunker Fieberg
Bruce C Marshall
Debra A Cibene
Frank J Accurso
Jane L Burns
Lisa Saiman
Macrolide Study Group
Nicole Mayer-Hamblett
Preston W Campbell
P304
P356
10.1001/JAMA.290.13.1749
P407
P577
2003-10-01T00:00:00Z